anti-CD20 antibodies

同

rituximab

同

rituximab

WordNet

1. not in favor of (an action or proposal etc.)
2. a person who is opposed (to an action or policy or practice etc.); "the antis smelled victory after a long battle"
3. social insect living in organized colonies; characteristically the males and fertile queen have wings during breeding season; wingless sterile females are the workers (同)emmet, pismire

PrepTutorEJDIC

1. 《話》(特定の慣習・政策・行動などに)反対する人
2. 『アリ』
3. =ain't
4. certificate of deposit / (また『C.D.』)Civil Defense民間防衛
5. (次にくる語の発音が母音で始まるときに用いる) / (子音[h]で始まり第1音節に強勢のない語の場合はanを用いることがある.ただし,この場合は[h]を発音しない)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 1型糖尿病の予防 prevention of type 1 diabetes mellitus
• 2. 多発血管炎性肉芽腫症を伴う肉芽腫症および関連血管炎の病因 pathogenesis of granulomatosis with polyangiitis and related vasculitides
• 3. 関節リウマチに対するリツキシマブおよびその他のB細胞標的療法 rituximab and other b cell targeted therapies for rheumatoid arthritis
• 4. 腎移植におけるHLAとABOの感作および脱感作 hla and abo sensitization and desensitization in renal transplantation
• 5. 成人の腎移植における免疫抑制誘導療法 induction immunosuppressive therapy in renal transplantation in adults

English Journal

• Plasma cell rich acute rejections (PCARs) in living related kidney transplantation: A Clinicopathological study of 50 cases.

• Abbas K1, Mubarak M1, Zafar MN1, Aziz T2, Haider A2, Muzaffar R1, Rizvi S3.
• Clinical transplantation.Clin Transplant.2015 Jul 14. doi: 10.1111/ctr.12589. [Epub ahead of print]
• BACKGROUND: Acute rejections (ARs) with plasma cell rich infiltrates (PCAR) are associated with poor outcomes.PATIENTS AND METHODS: Between February 2012 and December 2013, 1630 dysfunctional renal graft biopsies were performed. Of these, 50 (3%) showed PCAR. ARs with > 10% plasma cells were defi
• PMID 26172154

• Regulatory T cells and Minimal Change Nephropathy: in the mid of a complex network.

• Bertelli R1, Bonanni A2,1, Di Donato A1, Cioni M1, Ravani P3, Ghiggeri GM2,1.
• Clinical and experimental immunology.Clin Exp Immunol.2015 Jul 2. doi: 10.1111/cei.12675. [Epub ahead of print]
• Minimal Change Nephrosis (MCN) is an important cause of morbidity in children. In spite successful therapies have been developed in last 3 decades, most aspects related to pathogenesis still remain poorly defined. Evolution in basic immunology and results deriving from animal models of the disease s
• PMID 26147676

• Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.

• Österborg A1, Wierda WG2,3, Mayer J4, Hess G5, Hillmen P6, Schetelig J7, Schuh A8, Smolej L9, Beck C10, Dreyfus B11, Hellman A12, Kozlowski P13, Pfreundschuh M14, Rizzi R15, Spacek M16, Phillips JL17, Gupta IV17, Williams V18, Jewell RC18, Nebot N18, Lisby S19, Dyer MJ20.
• British journal of haematology.Br J Haematol.2015 Jul;170(1):40-9. doi: 10.1111/bjh.13380. Epub 2015 Mar 30.
• There are limited data on retreatment with monoclonal antibodies (mAb) in patients with chronic lymphocytic leukaemia (CLL). In a pivotal study, ofatumumab (human anti-CD20 mAb) monotherapy demonstrated a 47% objective response rate (ORR) in fludarabine refractory CLL patients. From this study, a su
• PMID 25825041

Japanese Journal

• 抗CD20抗体薬と抗CD52抗体薬 (特集 抗体によるがん分子標的治療) -- (がん領域の抗体薬)

• 石澤 賢一
• 最新医学 69(3), 379-385, 2014-03
• NAID 40020007546

• 新たな抗CD20モノクローナル抗体 (特集 リンパ腫に対する新しい治療選択)

• 冨田 章裕,島田 和之
• 腫瘍内科 11(3), 332-341, 2013-03
• NAID 40019669256

• 抗CD20抗体の作用機序による使い分けと新規薬剤の特長,開発の現状 (特集 血液内科領域における抗腫瘍薬の作用機序・副作用に基づく使い分け)

• 安部 康信,鵜池 直邦
• 血液内科 65(4), 465-472, 2012-10
• NAID 40019489449

Related Links

• Anti-CD20 monoclonal antibodies: historical and future ...

Fc:FcR dependent mechanisms Although the evidence regarding the involvement of CDC and PCD remains inconclusive, it is clear that Fc:FcγR interactions are critical for the success of anti-CD20 immunotherapy. FcγR ...

• CD20 Antibodies - Antibody Resource Page

CD20 antibodies FAB4225A Mouse Anti-CD20 antibody, Monoclonal[396444], Far-Red 100 Test Hu FACS Datasheet FAB4225P Mouse Anti-CD20 antibody, Monoclonal[396444], Red 100 Test Hu FACS Datasheet FAB4225F FITC ...

Related Pictures

---

★リンクテーブル★

関連記事	「CD2」「CD20」「CD」「ant」「anti」

「CD2」

　　[★]

同

Leucine-5, SRBC receptor, LFA-2

関

CD

発現細胞

• T細胞、胸腺細胞、NK細胞

分子量

• 45-58

機能

• 接着分子、CD58(LFA-3)に結合。細胞内部でLckに結合し、T細胞を活性化

• リンパ球が抗原提示細胞と相互作用するのに重要 (IMM.343)

別名

• LFA-2, T11

ファミリー

• immunoglobulin

「CD20」

　　[★]

発現細胞

• B細胞

分子量

• 33-37kDa

機能

• Ca²⁺のイオンチャネル(オリゴマー化して)。
• 多分、B細胞活性化の調節に関与

ファミリー

• cantains 4 transmembrane segments

同

B1

「CD」

　　[★]

• 表面抗原分類 cluster of differentiation
• 膠原病 collagen disease
• 集合管 collecting duct
• クローン病 Crohn's disease

　

「ant」

　　[★]

• n.

• アリ

同

ants, stinging

　 　 　

「anti」

　　[★]

• comb form.

• 抗、アンチ